Literature DB >> 30538775

FDG PET/CT and Conventional Imaging Methods in Cancer of Unknown Primary: an Approach to Overscanning.

Neslihan Cetin Avci1, Filiz Hatipoglu2, Ahmet Alacacıoglu3, Emine Ebru Bayar2, Gonca Gul Bural4.   

Abstract

PURPOSE: To compare the performance of fluorine-18 fluorodeoxyglucose positron emission tomography and computed tomography (FDG PET/CT) with conventional imaging methods (CIM), including computed tomography (CT), magnetic resonance imaging (MRI), and mammography (MMG) in cancer of unknown primary (CUP).
METHODS: A total of 36 patients with CUP, who referred to our clinic for a FDG PET/CT scan, were enrolled in this study. Thirty of the patients were also examined through either diagnostic CT/MRI and/or MMG. The diagnostic performance of both methods for the primary cancer location was analyzed. The results of FDG PET/CT and CIM were compared based on the standard reference of the histopathology and/or clinical and laboratory follow-up.
RESULTS: The primary cancer locations were detected in 24 patients (66.6%, 24/36) by FDG PET/CT, whereas CIM identified the locations in 16 patients (53.3%, 16/30). Sensitivity, specificity, PPV, NPV, and accuracy rates of the detection of the primary tumor localizations were as follows: 83, 70, 89, 58, and 79% for FDG PET/CT; 70, 62, 84, 42, and 68% for CIM, respectively. There was no statistical significance between modalities regarding any of the categories in 30 patients.
CONCLUSION: FDG PET/CT detected the primary tumors of the patients with CUP more than CIM did. However, the difference between them was not found to be statistically significant. It may be considered that FDG PET/CT scan can be performed as a first-line tool in the initial diagnosis of the patients with CUP and to add radiodiagnostic imaging in selective cases. We conclude that if the first-line examination of a CUP patient has been already performed by a CIM and the result was negative or inconclusive, FDG PET/CT can be considered to avoid unnecessary imaging procedures.

Entities:  

Keywords:  CT; Cancer of unknown primary origin; FDG PET/CT; MRI; Oncology

Year:  2018        PMID: 30538775      PMCID: PMC6261859          DOI: 10.1007/s13139-018-0544-7

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  19 in total

Review 1.  FDG-PET/CT for detection of the unknown primary head and neck tumor.

Authors:  J Johansen; H Petersen; C Godballe; A Loft; C Grau
Journal:  Q J Nucl Med Mol Imaging       Date:  2011-10       Impact factor: 2.346

2.  Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.

Authors:  Sung Shine Shim; Kyung Soo Lee; Byung-Tae Kim; Myung Jin Chung; Eun Jung Lee; Joungho Han; Joon Young Choi; O Jung Kwon; Young Mog Shim; Seonwoo Kim
Journal:  Radiology       Date:  2005-07-12       Impact factor: 11.105

3.  Detection of occult primary tumors in patients with cervical metastases of unknown primary tumors: comparison of (18)F FDG PET/CT with contrast-enhanced CT or CT/MR imaging-prospective study.

Authors:  Jae Ryung Lee; Jae Seung Kim; Jong-Lyel Roh; Jeong Hyun Lee; Jung Hwan Baek; Kyung-Ja Cho; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  Radiology       Date:  2014-11-17       Impact factor: 11.105

4.  A prospective comparison of 18F-FDG PET/CT and CT as diagnostic tools to identify the primary tumor site in patients with extracervical carcinoma of unknown primary site.

Authors:  Anne Kirstine H Møller; Annika Loft; Anne K Berthelsen; Karen D Pedersen; Jesper Graff; Charlotte B Christensen; Junia C Costa; Lene T Skovgaard; Katharina Perell; Bodil L Petersen; Gedske Daugaard
Journal:  Oncologist       Date:  2012-06-18

5.  Unknown primary tumors: detection with dual-modality PET/CT--initial experience.

Authors:  Andreas Gutzeit; Gerald Antoch; Hilmar Kühl; Thomas Egelhof; Markus Fischer; Elke Hauth; Susanne Goehde; Andreas Bockisch; Jörg Debatin; Lutz Freudenberg
Journal:  Radiology       Date:  2004-11-24       Impact factor: 11.105

6.  Staging of untreated nasopharyngeal carcinoma with PET/CT: comparison with conventional imaging work-up.

Authors:  Shu-Hang Ng; Sheng-Chieh Chan; Tzu-Chen Yen; Joseph Tung-Chieh Chang; Chun-Ta Liao; Sheung-Fat Ko; Feng-Yuan Liu; Shu-Chyn Chin; Kang-Hsing Fan; Cheng-Lung Hsu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-15       Impact factor: 9.236

7.  Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site.

Authors:  E Pelosi; M Pennone; D Deandreis; A Douroukas; M Mancini; G Bisi
Journal:  Q J Nucl Med Mol Imaging       Date:  2006-03       Impact factor: 2.346

8.  Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology.

Authors:  Gerald Antoch; Florian M Vogt; Lutz S Freudenberg; Fridun Nazaradeh; Susanne C Goehde; Jörg Barkhausen; Gerlinde Dahmen; Andreas Bockisch; Jörg F Debatin; Stefan G Ruehm
Journal:  JAMA       Date:  2003-12-24       Impact factor: 56.272

9.  Appropriateness criteria of FDG PET/CT in oncology.

Authors:  Archi Agrawal; Venkatesh Rangarajan
Journal:  Indian J Radiol Imaging       Date:  2015 Apr-Jun

10.  Combined FDG-PET/CT for the detection of unknown primary tumors: systematic review and meta-analysis.

Authors:  Thomas C Kwee; Robert M Kwee
Journal:  Eur Radiol       Date:  2008-10-17       Impact factor: 5.315

View more
  2 in total

1.  Comparison of FDG-PET/CT for Cancer Detection in Populations With Different Risks of Underlying Malignancy.

Authors:  Hung-Pin Chan; Wen-Shan Liu; Wen-Shiung Liou; Chin Hu; Yu-Li Chiu; Nan-Jing Peng
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

2.  Sentinel node theory helps tracking of primary lesions of cancers of unknown primary.

Authors:  Yilin Shao; Xin Liu; Silong Hu; Yingjian Zhang; Wentao Li; Xiaoyan Zhou; Qifeng Wang; Yifeng Hou; Yong Chen; Yanli Wang; Yaohui Wang; Zhiguo Luo; Xichun Hu
Journal:  BMC Cancer       Date:  2020-07-09       Impact factor: 4.430

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.